SG11202113154YA - Tead inhibitors and uses thereof - Google Patents
Tead inhibitors and uses thereofInfo
- Publication number
- SG11202113154YA SG11202113154YA SG11202113154YA SG11202113154YA SG11202113154YA SG 11202113154Y A SG11202113154Y A SG 11202113154YA SG 11202113154Y A SG11202113154Y A SG 11202113154YA SG 11202113154Y A SG11202113154Y A SG 11202113154YA SG 11202113154Y A SG11202113154Y A SG 11202113154YA
- Authority
- SG
- Singapore
- Prior art keywords
- tead
- inhibitors
- tead inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/27—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C305/00—Esters of sulfuric acids
- C07C305/26—Halogenosulfates, i.e. monoesters of halogenosulfuric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855082P | 2019-05-31 | 2019-05-31 | |
US201962928931P | 2019-10-31 | 2019-10-31 | |
US201962944567P | 2019-12-06 | 2019-12-06 | |
US202063025336P | 2020-05-15 | 2020-05-15 | |
PCT/US2020/035111 WO2020243423A1 (en) | 2019-05-31 | 2020-05-29 | Tead inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202113154YA true SG11202113154YA (en) | 2021-12-30 |
Family
ID=71787056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202113154YA SG11202113154YA (en) | 2019-05-31 | 2020-05-29 | Tead inhibitors and uses thereof |
Country Status (15)
Country | Link |
---|---|
US (2) | US11458149B1 (en) |
EP (1) | EP3976192A1 (en) |
JP (1) | JP2022534425A (en) |
KR (1) | KR20220034739A (en) |
CN (1) | CN114502540A (en) |
AU (1) | AU2020282759A1 (en) |
BR (1) | BR112021024224A2 (en) |
CA (1) | CA3141826A1 (en) |
CL (1) | CL2021003191A1 (en) |
CO (1) | CO2021016018A2 (en) |
IL (1) | IL288381A (en) |
MX (1) | MX2021014441A (en) |
SG (1) | SG11202113154YA (en) |
TW (1) | TW202108559A (en) |
WO (1) | WO2020243423A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019362788A1 (en) * | 2018-10-15 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof |
AU2020282757A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
EP3976597A1 (en) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica NV | Small molecule inhibitors of nf-kb inducing kinase |
MX2021014441A (en) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Tead inhibitors and uses thereof. |
JP2023530231A (en) * | 2020-06-03 | 2023-07-14 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Transcriptional enhancing associated domain (TEAD) inhibitor and use thereof |
US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
KR20230113278A (en) * | 2020-09-30 | 2023-07-28 | 카톨리에케 유니버시테이트 루벤 | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of YAP/TAZ-TEAD activation to treat cancer |
WO2022120354A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
EP4281073A1 (en) | 2021-01-25 | 2023-11-29 | Ikena Oncology, Inc. | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
AU2022258968A1 (en) | 2021-04-16 | 2023-10-19 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
CN115466243A (en) * | 2021-06-11 | 2022-12-13 | 武汉人福创新药物研发中心有限公司 | Heterocyclic compounds for TEAD inhibitors |
US20230115350A1 (en) * | 2021-07-29 | 2023-04-13 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
KR20240055778A (en) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Pharmaceutical combinations comprising TEAD inhibitors and their use for the treatment of cancer |
WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023099592A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202340209A (en) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
WO2023099620A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
TW202340208A (en) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
WO2023099624A1 (en) | 2021-12-01 | 2023-06-08 | Boehringer Ingelheim International Gmbh | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
TW202337432A (en) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023122781A2 (en) * | 2021-12-23 | 2023-06-29 | The Katholieke Universiteit Leuven | Tetrahydrobenzoazepinones and related analogs for inhibiting yap/taz-tead |
CN116332922A (en) * | 2021-12-24 | 2023-06-27 | 武汉人福创新药物研发中心有限公司 | Heterocyclic compounds as TEAD inhibitors |
KR20230110448A (en) * | 2022-01-14 | 2023-07-24 | 주식회사 대웅제약 | A novel aminobenzene derivative having a cancer cell growth inhibitory effect and a preventive or therapeutic pharmaceutical composition containing the same as an active ingredient |
TW202340180A (en) * | 2022-01-30 | 2023-10-16 | 大陸商希格生科(深圳)有限公司 | Tricyclic compound and use thereof |
WO2023154811A2 (en) * | 2022-02-09 | 2023-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | Transcriptional enhanced associate domain (tead) degraders and uses thereof |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023183437A1 (en) * | 2022-03-22 | 2023-09-28 | Sporos Biodiscovery, Inc. | Tead inhibitors and methods of use |
TW202404581A (en) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek inhibitors and uses thereof |
WO2024020350A1 (en) * | 2022-07-21 | 2024-01-25 | Sporos Biodiscovery, Inc. | Tead inhibitors and methods of use |
KR20240014034A (en) * | 2022-07-21 | 2024-01-31 | 주식회사 바오밥에이바이오 | Heterobicyclic Compound and Pharmaceutical Composition Comprising the Same |
WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3120564A (en) | 1960-01-13 | 1964-02-04 | American Cyanamid Co | Alkenoylamino benzophenones |
ZA825719B (en) | 1981-09-03 | 1983-06-29 | Recordati Chem Pharm | Alkanoylanilides |
JPS58179838A (en) | 1982-04-14 | 1983-10-21 | Konishiroku Photo Ind Co Ltd | Formation of image |
US5256791A (en) | 1992-03-02 | 1993-10-26 | Pfizer Inc. | Preparation of intermediates in the synthesis of quinoline antibiotics |
DE4341403A1 (en) | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituted 3-azabicycloalkane derivatives, their preparation and use |
US5475116A (en) | 1994-04-29 | 1995-12-12 | Pfizer Inc. | Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones |
JPH0912547A (en) | 1995-06-23 | 1997-01-14 | Chisso Corp | Production of intermediate for new quinolone-based compound |
WO1997030030A1 (en) | 1996-02-13 | 1997-08-21 | Chugai Seiyaku Kabushiki Kaisha | Indole derivatives |
US5968929A (en) | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US6184380B1 (en) | 1999-01-25 | 2001-02-06 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
US7019142B2 (en) | 1998-01-16 | 2006-03-28 | Pfizer Inc. | Process for preparing naphthyridones and intermediates |
US6590118B1 (en) | 1999-09-29 | 2003-07-08 | Novo Nordisk A/S | Aromatic compounds |
EE05351B1 (en) | 1999-12-10 | 2010-10-15 | Pfizer Products Inc. | Pyrrolo [2,3-d] pyrimidine compounds |
KR20020073586A (en) | 2000-02-11 | 2002-09-27 | 버텍스 파마슈티칼스 인코포레이티드 | Piperazine and piperidine derivatives |
DE60119047D1 (en) | 2000-08-31 | 2006-06-01 | Pfizer | Phenoxyphenyl heterocycles as serotonin reuptake inhibitors |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
WO2002032901A2 (en) | 2000-10-19 | 2002-04-25 | Pfizer Products Inc. | Bridged piperazine derivatives |
GEP20053675B (en) | 2001-03-30 | 2005-11-25 | Pfizer Prod Inc | Pyridazinone Aldose Reductase Inhibitors |
CA2445395C (en) | 2001-04-27 | 2010-03-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US20040034019A1 (en) | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
SI1536827T1 (en) | 2002-08-14 | 2009-06-30 | Silence Therapeutics Ag | Use of protein kinase n beta |
AU2003273762A1 (en) | 2002-10-28 | 2004-05-13 | Novo Nordisk A/S | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
US20040082641A1 (en) | 2002-10-28 | 2004-04-29 | Rytved Klaus Asger | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
US7232835B2 (en) | 2002-12-10 | 2007-06-19 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists |
AU2002356369A1 (en) | 2002-12-23 | 2004-07-14 | Ranbaxy Laboratories Limited | Xanthine derivatives as muscarinic receptor antagonists |
US7501443B2 (en) | 2002-12-23 | 2009-03-10 | Ranbaxy Laboratories Limited | Flavaxate derivatives as muscarinic receptor antagonists |
US7488748B2 (en) | 2003-01-28 | 2009-02-10 | Ranbaxy Laboratories Limited | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
JP2006523237A (en) | 2003-04-03 | 2006-10-12 | セマフォア ファーマシューティカルズ, インコーポレイテッド | PI-3 kinase inhibitor prodrug |
KR101168441B1 (en) | 2003-05-30 | 2012-07-25 | 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
AU2004257167B2 (en) | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
KR20060095865A (en) | 2003-10-14 | 2006-09-04 | 화이자 프로덕츠 인크. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
CA2554378A1 (en) | 2004-02-18 | 2005-08-25 | Kyorin Pharmaceutical Co., Ltd. | Bicycloamide derivative |
PL3153514T3 (en) | 2004-05-13 | 2022-01-10 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
ATE444066T1 (en) | 2004-06-22 | 2009-10-15 | Schering Corp | LIGANDS FOR THE CANNABINOID RECEPTORS |
BRPI0514820A (en) | 2004-09-01 | 2008-06-24 | Pfizer Prod Inc | Azabicyclic histamine-3 amine receptor antagonists |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
EP1828174A1 (en) | 2004-11-19 | 2007-09-05 | Ranbaxy Laboratories Limited | Azabicyclic muscarinic receptor antagonists |
CN1944398A (en) | 2005-01-11 | 2007-04-11 | 中国医学科学院药物研究所 | New benzoyl amide compounds and its preparing method and medicine use |
BRPI0606318B8 (en) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | compound, composition, and use of a compound |
DK1866339T3 (en) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-binding molecules and their applications |
UA88518C2 (en) | 2005-04-08 | 2009-10-26 | Пфайзер Продактс Инк. | Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors |
US20090124600A1 (en) | 2005-04-19 | 2009-05-14 | Layton Mark E | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists |
CA2607670A1 (en) | 2005-05-10 | 2006-11-16 | Vertex Pharmaceuticals Incorporated | Bicyclic derivatives as modulators of ion channels |
CN101175738B (en) | 2005-05-12 | 2010-10-27 | 雅培制药有限公司 | Apoptosis promoters |
GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP5252635B2 (en) | 2005-07-01 | 2013-07-31 | メダレックス インコーポレーティッド | Human monoclonal antibody against programmed death ligand 1 (PD-L1) |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
US20080300251A1 (en) * | 2005-09-05 | 2008-12-04 | Sattigeri Jitendra A | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors |
DK1931645T3 (en) | 2005-10-07 | 2014-09-29 | Exelixis Inc | N- (3-aminoquinoxalin-2-yl) -sulfonamide derivatives and their use as inhibitors of phosphatidylinositol-3-kinase |
WO2007045979A1 (en) | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
BR122021011787B1 (en) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Biaryl metapyrimidine kinase inhibitors, pharmaceutical composition and process for preparing a pharmaceutical composition |
DK2455382T3 (en) | 2005-12-13 | 2017-01-02 | Incyte Holdings Corp | Heteroberl substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
DE602007007323D1 (en) | 2006-04-26 | 2010-08-05 | Hoffmann La Roche | THIENOÄ3,2-DÜPYRIMIDINE DERIVATIVE SUITABLE AS PI3K INHIBITOR |
WO2008010061A2 (en) | 2006-07-17 | 2008-01-24 | Glenmark Pharmaceuticals S.A. | 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation |
AU2007274598A1 (en) | 2006-07-21 | 2008-01-24 | Lupin Limited | Antidiabetic azabicyclo [3. 1. 0] hexan compounds |
PE20080948A1 (en) | 2006-07-25 | 2008-09-10 | Irm Llc | IMIDAZOLE DERIVATIVES AS MODULATORS OF THE HEDGEHOG PATH |
WO2008029349A2 (en) | 2006-09-04 | 2008-03-13 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
KR101315610B1 (en) | 2006-09-22 | 2013-10-10 | 파마시클릭스, 인코포레이티드 | Inhibitors of bruton's tyrosine kinase |
CA2672373C (en) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
EP2132196A1 (en) | 2007-02-26 | 2009-12-16 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
KR101737753B1 (en) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | Phenyl amino pyrimidine compounds and uses thereof |
WO2008117229A1 (en) * | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
TW200932236A (en) | 2007-10-31 | 2009-08-01 | Janssen Pharmaceutica Nv | Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase |
JP5583592B2 (en) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | IDO inhibitor |
EA017218B1 (en) | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Azetidine and cyclobutane derivatives as jak inhibitors |
WO2009156652A1 (en) | 2008-05-29 | 2009-12-30 | Saint-Gobain Centre De Recherches Et D'etudes Europeen | Cellular structure containing aluminium titanate |
WO2009152027A1 (en) | 2008-06-12 | 2009-12-17 | Merck & Co., Inc. | 5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
PE20110547A1 (en) | 2008-10-29 | 2011-08-04 | Celgene Corp | ISOINDOLINE COMPOUNDS WITH ANTI-CANCER ACTIVITY |
LT4209510T (en) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
AU2010233378A1 (en) * | 2009-04-08 | 2011-11-24 | Actelion Pharmaceuticals Ltd. | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as ADP receptor antagonists |
US9149465B2 (en) | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
AR076687A1 (en) | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | ISOXAZOLINS AS INHIBITORS OF THE AMIDAHIDROLASA OF FATTY ACIDS AND PHARMACEUTICAL COM-POSITIONS CONTAINING THEM |
CN102574924A (en) | 2009-09-03 | 2012-07-11 | 先灵公司 | Anti-gitr antibodies |
RS58693B1 (en) | 2009-12-10 | 2019-06-28 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
JP5998060B2 (en) | 2010-03-04 | 2016-09-28 | マクロジェニクス,インコーポレーテッド | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
EP2542588A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
KR101656548B1 (en) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | Antibodies against human csf-1r and uses thereof |
TWI713942B (en) | 2010-05-04 | 2020-12-21 | 美商戊瑞治療有限公司 | Antibodies that bind csf1r |
AU2011279845B8 (en) | 2010-07-23 | 2014-11-20 | Merck Sharp & Dohme Corp. | Novel pyrrolidine derived beta 3 adrenergic receptor agonists |
SG10201506906VA (en) | 2010-09-09 | 2015-10-29 | Pfizer | 4-1bb binding molecules |
JP5947311B2 (en) | 2010-12-09 | 2016-07-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Use of chimeric antigen receptor modified T cells for the treatment of cancer |
US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
NO2694640T3 (en) | 2011-04-15 | 2018-03-17 | ||
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
WO2013018929A1 (en) | 2011-08-04 | 2013-02-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
EP2755656B1 (en) | 2011-09-16 | 2016-09-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
CN103380131B (en) | 2011-09-19 | 2015-12-02 | 苏文生命科学有限公司 | As the heteroaryl compound of 5-HT4 receptors ligand |
AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
WO2013118138A1 (en) | 2011-12-13 | 2013-08-15 | Laboratories Ltd Mylan | Novel process for the preparation of renin inhibitors |
RU2658603C2 (en) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Antibodies against human csf-1r and uses thereof |
TWI566701B (en) | 2012-02-01 | 2017-01-21 | 日本農藥股份有限公司 | Arylalkyloxypyrimidine derivatives and agrohorticultural insecticides comprising said derivatives as active ingredients, and method of use thereof |
RU2014136332A (en) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | COMPOSITIONS AND METHODS OF APPLICATION OF CSF1R INHIBITORS |
AR090263A1 (en) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
CA2871445C (en) | 2012-05-11 | 2020-07-07 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
AR091649A1 (en) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
WO2014036357A1 (en) | 2012-08-31 | 2014-03-06 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
WO2014085210A1 (en) | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9505781B2 (en) | 2013-03-13 | 2016-11-29 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
BR112015022483A2 (en) | 2013-03-14 | 2017-07-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant idh inhibitors |
KR101556318B1 (en) | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | Novel 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors |
WO2014199164A1 (en) | 2013-06-12 | 2014-12-18 | Ampla Pharmaceuticals, Inc. | Diaryl substituted heteroaromatic compounds |
EP3019154B1 (en) | 2013-07-11 | 2020-09-02 | Alexza Pharmaceuticals, Inc. | Nicotine salt with meta-salicylic acid |
PL3193880T3 (en) | 2014-09-19 | 2020-09-07 | Eli Lilly And Company | Inhibiting the transient receptor potential a1 ion channel |
CN106432255A (en) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | Fumigillol spiro-compound, preparation and use method thereof |
AR105889A1 (en) | 2015-09-03 | 2017-11-22 | Actelion Pharmaceuticals Ltd | ANTIBACTERIAL COMPOUNDS 1,2-DIHIDRO-3H-PIRROLO [1,2-C] IMIDAZOL-3-ONA SUBSTITUTED |
US10696642B2 (en) * | 2015-09-23 | 2020-06-30 | The General Hospital Corporation | TEAD transcription factor autopalmitoylation inhibitors |
WO2017058716A1 (en) | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
US20170158702A1 (en) | 2015-12-02 | 2017-06-08 | Kyras Therapeutics, Inc. | Multivalent ras binding compounds |
CA3228632A1 (en) | 2015-12-24 | 2017-06-29 | Kyowa Kirin Co., Ltd. | .alpha.,.beta.-unsaturated amide compound |
RU2696269C1 (en) | 2015-12-29 | 2019-08-01 | Пфайзер Инк. | Substituted 3-azabicyclo[3_1_0]hexanes as ketohexokinase inhibitors |
GEP20207130B (en) | 2016-05-31 | 2020-07-10 | Chiesi Farm Spa | Imidazolone compounds as human neutrophil elastase inhibitors |
WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
CN109561682B (en) * | 2016-06-27 | 2021-05-11 | 牧牛研究所株式会社 | Pyridines comprising an isoxazoline ring and their use as herbicides |
KR102444836B1 (en) | 2016-08-23 | 2022-09-19 | 리커리엄 아이피 홀딩스, 엘엘씨 | Cross-coupling method |
AU2017341723B2 (en) | 2016-10-11 | 2021-12-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
WO2018136437A2 (en) * | 2017-01-17 | 2018-07-26 | Tesaro, Inc. | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
EP3606921B1 (en) | 2017-04-06 | 2022-06-01 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma. |
CA3062294A1 (en) | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
EP3621961A4 (en) | 2017-05-10 | 2020-09-09 | Forge Therapeutics, Inc. | Antibacterial compounds |
KR20200019979A (en) | 2017-06-23 | 2020-02-25 | 쿄와 기린 가부시키가이샤 | α, β unsaturated amide compounds |
AU2018321291A1 (en) * | 2017-08-21 | 2020-03-26 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
TWI793151B (en) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW201920108A (en) | 2017-09-25 | 2019-06-01 | 日商武田藥品工業有限公司 | N-(cyano-substituted benzyl or pyridinylmethyl)-3-hydroxypicolinamide derivatives |
US10287222B1 (en) | 2017-10-20 | 2019-05-14 | Uop Llc | Process and apparatus for desorbent recovery |
CA3079833A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
EP3704106B1 (en) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
WO2019113236A1 (en) | 2017-12-06 | 2019-06-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
AU2019216492A1 (en) | 2018-02-02 | 2020-08-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
TW202012396A (en) | 2018-04-18 | 2020-04-01 | 美商德洛斯股份有限公司 | K-ras modulators with a vinyl sulfonamide moiety |
JP7394074B2 (en) | 2018-05-31 | 2023-12-07 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | therapeutic compounds |
JP2021535169A (en) | 2018-09-03 | 2021-12-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Carboxamide and sulfonamide derivatives useful as TEAD modulators |
WO2020073031A1 (en) | 2018-10-05 | 2020-04-09 | New York University | Fused bicyclic heterocycles as thereapeutic agents |
AU2019362788A1 (en) | 2018-10-15 | 2021-04-15 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (TEAD) transcription factor inhibitors and uses thereof |
EP3867242A1 (en) | 2018-10-15 | 2021-08-25 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
US20210403415A1 (en) | 2018-10-26 | 2021-12-30 | The Trustees Of Indiana University | Compounds and methods to attenuate tumor progression and metastasis |
KR102615551B1 (en) | 2018-12-14 | 2023-12-20 | 주식회사유한양행 | 3,3-difluoroallylamine or its salt and pharmaceutical composition containing the same |
CA3124935A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN113811300A (en) | 2019-03-15 | 2021-12-17 | 总医院公司 | Novel small molecule inhibitors of TEAD transcription factor |
EP3947368A4 (en) | 2019-04-04 | 2023-01-04 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
AU2020263390A1 (en) | 2019-04-23 | 2021-10-07 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof |
MX2021014441A (en) | 2019-05-31 | 2022-01-06 | Ikena Oncology Inc | Tead inhibitors and uses thereof. |
KR20220016498A (en) | 2019-05-31 | 2022-02-09 | 키에시 파르마슈티시 엣스. 피. 에이. | Aminoquinazoline derivatives as P2X3 inhibitors |
AU2020282757A1 (en) | 2019-05-31 | 2021-12-23 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
EP3976597A1 (en) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica NV | Small molecule inhibitors of nf-kb inducing kinase |
AU2020296361A1 (en) | 2019-06-18 | 2022-01-06 | Ctxt Pty Ltd | Benzisoxazole sulfonamide derivatives |
JP2023501989A (en) | 2019-11-13 | 2023-01-20 | ジェネンテック, インコーポレイテッド | Therapeutic compounds and methods of use |
JOP20220130A1 (en) | 2019-12-06 | 2023-01-30 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
WO2021133896A1 (en) | 2019-12-24 | 2021-07-01 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate doman (tead) transcription factor inhibitors and uses thereof |
JP2023516645A (en) | 2020-03-04 | 2023-04-20 | ジェネンテック, インコーポレイテッド | Heterobifunctional molecules as TEAD inhibitors |
JP2023530231A (en) | 2020-06-03 | 2023-07-14 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Transcriptional enhancing associated domain (TEAD) inhibitor and use thereof |
WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
WO2022120354A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
EP4281073A1 (en) | 2021-01-25 | 2023-11-29 | Ikena Oncology, Inc. | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
-
2020
- 2020-05-29 MX MX2021014441A patent/MX2021014441A/en unknown
- 2020-05-29 BR BR112021024224A patent/BR112021024224A2/en unknown
- 2020-05-29 EP EP20746357.1A patent/EP3976192A1/en active Pending
- 2020-05-29 WO PCT/US2020/035111 patent/WO2020243423A1/en unknown
- 2020-05-29 JP JP2021570915A patent/JP2022534425A/en not_active Withdrawn
- 2020-05-29 US US16/887,083 patent/US11458149B1/en active Active
- 2020-05-29 TW TW109118217A patent/TW202108559A/en unknown
- 2020-05-29 AU AU2020282759A patent/AU2020282759A1/en active Pending
- 2020-05-29 CA CA3141826A patent/CA3141826A1/en active Pending
- 2020-05-29 SG SG11202113154YA patent/SG11202113154YA/en unknown
- 2020-05-29 CN CN202080050334.3A patent/CN114502540A/en not_active Withdrawn
- 2020-05-29 KR KR1020217043144A patent/KR20220034739A/en unknown
-
2021
- 2021-11-25 IL IL288381A patent/IL288381A/en unknown
- 2021-11-26 CO CONC2021/0016018A patent/CO2021016018A2/en unknown
- 2021-11-30 CL CL2021003191A patent/CL2021003191A1/en unknown
-
2022
- 2022-08-02 US US17/816,859 patent/US11925651B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3976192A1 (en) | 2022-04-06 |
BR112021024224A2 (en) | 2022-04-26 |
CO2021016018A2 (en) | 2022-04-08 |
TW202108559A (en) | 2021-03-01 |
US11925651B2 (en) | 2024-03-12 |
US20230148061A1 (en) | 2023-05-11 |
US11458149B1 (en) | 2022-10-04 |
JP2022534425A (en) | 2022-07-29 |
MX2021014441A (en) | 2022-01-06 |
KR20220034739A (en) | 2022-03-18 |
AU2020282759A1 (en) | 2021-12-23 |
CA3141826A1 (en) | 2020-12-03 |
WO2020243423A1 (en) | 2020-12-03 |
IL288381A (en) | 2022-01-01 |
CL2021003191A1 (en) | 2022-05-06 |
CN114502540A (en) | 2022-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288381A (en) | Tead inhibitors and uses thereof | |
IL288384A (en) | Tead inhibitors and uses thereof | |
IL282487A (en) | Tyk2 inhibitors and uses thereof | |
IL276095A (en) | Gcn2 inhibitors and uses thereof | |
IL276147A (en) | Gcn2 inhibitors and uses thereof | |
IL289612A (en) | Hpk1 inhibitors and uses thereof | |
IL286248A (en) | Tyk2 inhibitors and uses thereof | |
IL284799A (en) | Tyk2 inhibitors and uses thereof | |
IL282090A (en) | Tyk2 inhibitors and uses thereof | |
IL283409A (en) | Tyk2 inhibitors and uses thereof | |
EP3572400C0 (en) | Ezh2 inhibitor and use thereof | |
IL289754A (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
IL272649B (en) | Ahr inhibitors and uses thereof | |
SI3621694T1 (en) | Lrrc33 inhibitors and use thereof | |
IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
IL291217A (en) | Usp30 inhibitors and uses thereof | |
IL286622A (en) | Prmt5 inhibitors and uses thereof | |
PT3712147T (en) | Sglts inhibitor and application thereof | |
IL284745A (en) | Gpr174 inhibitor containing compositions and uses thereof | |
EP3784650A4 (en) | Novel mct4 inhibitors and uses thereof | |
IL285595A (en) | Spt5 inhibitors and uses thereof | |
IL292198A (en) | Tim-3 inhibitors and uses thereof | |
IL279276A (en) | Erk inhibitor and use thereof | |
IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
IL291895A (en) | Mcl1 inhibitors and uses thereof |